Approaches to Breast-Cancer Staging
- 24 February 2000
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 342 (8) , 580-581
- https://doi.org/10.1056/nejm200002243420809
Abstract
Each year more than 180,000 women in the United States receive a diagnosis of breast cancer, and over 40,000 of them ultimately die of their disease. Larger primary tumors and tumor cells in axillary nodes are strong predictors of metastatic disease and death. In an effort to prevent these outcomes, women with tumor cells in axillary nodes routinely receive chemotherapy, hormonal therapy, or both, and radiation after surgery. Unfortunately, the predictive value of axillary-node status is limited. As many as 40 percent of women with positive axillary nodes survive 10 years, and metastatic disease develops within 10 years after diagnosis . . .Keywords
This publication has 9 references indexed in Scilit:
- Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II, or III Breast CancerNew England Journal of Medicine, 2000
- The Sentinel Node in Breast Cancer — A Multicenter Validation StudyNew England Journal of Medicine, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Adjuvant Radiotherapy and Chemotherapy in Node-Positive Premenopausal Women with Breast CancerNew England Journal of Medicine, 1997
- Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant ChemotherapyNew England Journal of Medicine, 1997
- Sentinel lymphadenectomy in breast cancer.Journal of Clinical Oncology, 1997
- Occult axillary node metastases in breast cancer: their detection and prognostic significanceBritish Journal of Cancer, 1996
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- NIH consensus conference. Treatment of early-stage breast cancerPublished by American Medical Association (AMA) ,1991